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A recent Hendra virus outbreak at a veterinary clinic 
in Brisbane, Queensland, Australia, involved 5 equine and 
2 human infections. In contrast to previous outbreaks, in-
fected horses had predominantly encephalitic, rather than 
respiratory, signs. After an incubation period of 9–16 days, 
inﬂ  uenza-like illnesses developed in the 2 persons before 
progressing to encephalitis; 1 died. Both patients were giv-
en ribavirin. Basal serum and cerebrospinal ﬂ  uid levels were 
10–13 mg/L after intravenous administration and 6 mg/L af-
ter oral administration (isolate 90% inhibitory concentration 
64 mg/L). Both patients were exposed to infected horses, 1 
during the late incubation period in a horse. The attack rate 
for veterinary clinic staff exposed to infected horses was 
10%. An isolate from this outbreak showed genetic hetero-
geneity with isolates from a concurrent, but geographically 
remote, outbreak and from previous outbreaks. Emergence 
of Hendra virus is a serious medical, veterinary, and public 
health challenge.
T
he genus Henipavirus of the family Paramyxoviridae 
contains 2 recently described viruses, Hendra virus 
and Nipah virus, whose natural reservoir is fruit bats of the 
genus Pteropus (1). Hendra virus has caused serious respi-
ratory infections in horses and respiratory and neurologic 
infections in humans. After 2 Hendra virus outbreaks in 
1994, which involved 22 horses and 3 humans (2,3), a to-
tal of 7 additional equine infections and 1 human infection 
were documented up to 2008 (4,5); all occurred in coastal 
Queensland and northern New South Wales in Australia. 
Of the 4 persons with documented Hendra virus infection, 
2 recovered from inﬂ  uenza-like illnesses (ILIs) (2,5) and 2 
died, 1 from respiratory failure (2) and 1 from encephalitis 
13 months after initial aseptic meningitis (3). The estimat-
ed incubation period in humans of 7–8 days was based on 
these cases.
The Outbreak
In early July 2008, a veterinary practice (clinic) in 
Thornlands, Queensland, was quarantined after 2 acutely 
ill horses were provisionally diagnosed with Hendra virus 
infection. Four horses eventually died from the infection, 
and another was humanely killed after it recovered, in ac-
cordance with established national veterinary practice (6). 
In contrast to previous equine outbreaks, horses in this out-
break showed predominantly neurologic (ataxia, head tilt, 
limb paresis), rather than respiratory, symptoms (1). We re-
port 2 additional human cases of Hendra virus encephalitis, 
1 fatal, in veterinary workers associated with this equine 
outbreak.
Patient 1
A 33-year-old man (equine veterinarian) at the clinic 
had a 2-day history of an ILI (fever, myalgia, and headache) 
in mid-July 2008. Clinical examination showed only a fe-
ver (38°C); mild neutropenia (0.7 × 109 cells/L) and throm-
bocytopenia (79 × 109 cells/L); a normal chest radiograph; 
and negative PCR results for respiratory viruses, including 
inﬂ  uenza, on a nasopharyngeal aspirate (NPA) specimen. 
Hendra virus RNA was detected by reverse transcription–
PCR (RT-PCR) in serum and NPA specimens. The patient 
remained clinically well and showed defervescence on day 
4 of illness.
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By day 5, mild confusion, ataxia, bilateral ptosis, but 
no other neurologic signs, developed. Magnetic resonance 
imaging (MRI) showed multifocal (bilateral, cerebral, 
cortical, right pontine, scattered white matter) hyperin-
tense lesions on T2 ﬂ  air images associated with evidence 
of infarction on diffusion weighted images. A cerebrospi-
nal ﬂ  uid (CSF) sample had a leukocyte count of 4 × 106 
cells/L, a protein level of 600 mg/L, and a glucose level of 
3.7 mmol/L; Hendra virus RNA was detected by RT-PCR. 
An electroencephalogram (EEG) showed bilateral high-
voltage slow waves but no epileptiform activity. He was 
treated with intravenous ribavirin (30 mg/kg initial dose, 
then 15 mg/kg every 6 h for 4 days, and 8 mg/kg every 8 
h thereafter); enteric aspirin (100 mg/day); and because of 
progressive confusion and ataxia, intravenous dexametha-
sone (4 mg every 6 h).
Over the next 4 days (to day 10) progressive neuro-
logic signs and high-grade fever developed, culminating in 
a generalized partial tonic-clonic seizure. During the next 
4 weeks, the patient required mechanical ventilation, re-
mained febrile, and despite control of seizure activity and 
minimal sedation, remained deeply unconscious with mini-
mally reactive pupils. Treatment with ribavirin was stopped 
after 12 days of therapy when the patient’s hemoglobin lev-
el decreased to 76 g/L. Serial MRI showed marked progres-
sion with innumerable cortical, subcortical, and brainstem 
hyperintense foci on T2 ﬂ  air images with matching diffu-
sion restriction, and leptomeningeal enhancement (Figure 
1, panel A). Serial EEGs showed an absence of a stable 
background rhythm, slow wave activity with periodic sharp 
discharges, and a right-sided epileptogenic focus. CSF on 
day 28 had a leukocyte count of 84 × 106 cells/L, a pro-
tein level of 650 mg/L, and a glucose level of 4.3 mmol/L; 
Hendra virus RNA was not detected by RT-PCR. He died 
on day 40 of illness. A postmortem examination was not 
performed because a risk assessment conducted by Queen-
sland Health concluded that an examination could not be 
performed in Queensland. 
Patient 2
A 21-year-old woman (veterinary nurse) at the same 
clinic was observed 4 days after patient 1 with a 3-day his-
tory of an ILI. Results of clinical examination were unre-
markable apart from a fever (39°C). Results of initial in-
vestigations, including complete blood examination, chest 
radiography, and EEG, were normal. Hendra virus RNA 
was detected in serum and NPA specimens. She was treat-
ed with intravenous ribavirin (30 mg/kg initial dose, then 
15 mg/kg every 6 h) and aspirin (100 mg/day). On day 12 
of illness, 96 hours after defervescence, encephalitic mani-
festations (mild confusion, dysarthria, ataxia, and bilateral 
ptosis) developed. Results of MRI and a CSF specimen 
were normal; Hendra virus was not detected by RT-PCR.
Over the next 12 days, signs of encephalitis deteriorated 
(ataxia, dysarthria) before stabilizing. Serial MRI showed 
scattered, small, hyperintense, cortical and subcortical foci 
on T2 ﬂ  air images and leptomeningeal enhancement (Fig-
ure 1, panel B), and EEGs showed severe diffuse encephal-
opathy with high-amplitude slow waves. Clinical and EEG 
improvement ensued, and the patient was discharged on 
day 37 with mild residual ataxia. By then, she had received 
32 days of intravenous ribavirin and had steady-state basal 
serum ribavirin levels of 10.1 mg/L and 13.1 mg/L and a 
CSF level of 9.9 mg/L (all obtained while she was receiving 
15 mg/kg every 6 h; J. Ray, pers. comm.).
Treatment with ribavirin was continued at a dosage of 
600 mg orally every 8 h (basal level 6.2 mg/L; J. Ray, pers. 
comm.), and she remained clinically well during 20 weeks 
of follow-up. Repeat MRI (at days 69 and 135 and month 
11) showed marked resolution in signal abnormalities, and 
EEGs (at days 69 and 182) also showed considerable im-
provement. A CSF sample obtained at month 12 showed 
normal results, including a negative result for Hendra virus 
by RT-PCR.
Results
Virologic and Serologic Findings
Serial quantitative RT-PCR for Hendra virus RNA (7) 
in serum, NPA, and urine specimens and serial immunoﬂ  u-
orescent antibody assay and microsphere immunoassay for 
immunoglobulin (Ig) G and IgM against Hendra virus (8) in 
serum were performed for both patients (online Appendix 
Table, www.cdc.gov/EID/content/16/2/219-appT.htm). Se-
roconversion of IgG against Hendra virus occurred on days 
5 and 11 in patients 1 and 2 respectively, and Hendra virus 
RNA was detected up to days 14 and 23, respectively.
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Figure 1. Magnetic resonance imaging scans of the brains of 2 
patients with Hendra virus encephalitis, Australia, 2008. A) Patient 
1 on day 18 of illness, showing cortical and subcortical hyperintense 
foci. B) Patient 2 on day 25 of illness, showing hyperintense foci in 
the left precentral gyrus (arrowhead).Human Hendra Virus Encephalitis, Australia, 2008
Direct PCR sequencing of clinical material from both 
patients was used to obtain nucleotide sequences for the 
nucleoprotein, matrix, glycoprotein, and accessory pro-
tein genes and the intragenic junctions. Results showed 
that Hendra virus associated with this outbreak was dis-
tinct from Hendra virus in a concurrent equine outbreak in 
Cannonvale in northern Queensland, Australia, and from 
viruses in previous outbreaks (Figure 2).
Virus isolated from Vero E6 cells (CRL-1586; Ameri-
can Type Culture Collection, Manassas, VA, USA) cul-
tured with an NPA sample obtained on day 5 of illness of 
patient 2 was used to test in vitro susceptibility to ribavirin 
(9). The 90% inhibitory concentration of ribavirin for this 
isolate was 64 mg/L.
Human Public Health Investigations and Responses
After conﬁ  rmation of equine Hendra virus cases, 83 
contacts of infected horses (37 veterinary clinic staff, 25 
owners/handlers, and 21 Department of Primary Industries 
staff) and 8 contacts of human case-patients (6 domestic 
contacts, and 2 healthcare workers) were contacted for as-
sessment and counseling. Nonspeciﬁ  c respiratory or gas-
trointestinal symptoms developed in 16 contacts of infected 
horses; none had Hendra virus RNA or antibodies against 
this virus in convalescent-phase serum samples (obtained 
>2 weeks after last exposure to infected horses or humans). 
One veterinary worker had percutaneous blood exposure 
while performing euthanasia on the Hendra virus–infected 
horse that recovered. This person was treated with a 5-day 
course of intravenous ribavirin (30 mg/kg initial dose, then 
15 mg/kg every 6 h) within 4 h after exposure. Serologic 
follow-up up to 25 weeks showed no evidence of infection 
with Hendra virus.
Degree of exposure to infected horses and use of per-
sonal protective equipment (PPE) were assessed in 28 vet-
erinary clinic staff. Twenty (including the 2 patients) re-
ported contact with potentially infected equine body ﬂ  uids; 
the Hendra virus attack rate for exposed staff was 10%. 
Fourteen identiﬁ   ed high-risk exposures (potential expo-
sure through unprotected mucous membrane, broken skin, 
or respiratory route), among whom self-reported use of 
PPE (respiratory droplet and mucosal protection) was low 
(7%). The other 6 staff identiﬁ  ed low-risk exposures (intact 
skin). High-risk exposures identiﬁ  ed among the 2 infected 
patients included performing daily nasal cavity lavage dur-
ing the last 3 days of the incubation period on 1 infected 
horse (9 and 11 days before illness onset in patients 1 and 
2, respectively) and participating in a necropsy of another 
infected horse (patient 1) 16 days before illness onset.
Discussion
Unlike previously recognized equine Hendra virus 
infections (1), this outbreak involved predominantly neu-
rologic, rather than respiratory, equine symptoms. This 
ﬁ  nding may have contributed to delayed recognition of the 
etiologic cause among the sick horses and thus unprotected 
exposure of human contacts.
Of the 4 persons previously infected with Hendra vi-
rus, 1 died from multiorgan failure, another died from en-
cephalitis 13 months after aseptic meningitis, and 2 others 
survived after ILIs. The 2 patients described in this report 
also had initial ILIs. However, soon after apparent clinical 
improvement, including defervescence, encephalitis de-
veloped in both patients. The MRI changes showed wide-
spread cortical, subcortical, and deep white matter involve-
ment, similar to those described in a previous Hendra virus 
encephalitis case (3) and Nipah virus encephalitis cases 
(10,11). These changes are consistent with the neuropatho-
genesis of Henipavirus-related encephalitis (widespread vi-
ral endothelial infection with resultant vasculitis, syncytial 
giant cell formation, and ischemic necrosis) (12). Although 
encephalitis developed in both patients 1–4 days after ini-
tial clinical improvement of the initial ILI and concurrent 
with the appearance of Hendra virus–speciﬁ  c antibodies, 
the ability of Henipaviruses to inhibit interferon signaling 
(13,14) is a major virulence factor that enables evasion of 
host responses. The other major phenomenon, described 
for 1 case of Hendra virus infection and in >5% and >10% 
of cases of Nipah virus encephalitic and nonencephalitic 
infections, respectively, is relapsed or late-onset encepha-
litic manifestations (3,15). However, the pathogenesis of 
this latency and understanding these clinical manifestations 
remain incomplete.
Given the previous demonstration of an in vitro ef-
fect of ribavirin against Hendra virus (16) and a reported 
survival beneﬁ  t associated with its use (predominantly by 
the enteral route of administration) compared with histori-
cal controls in Nipah virus encephalitis (17), our patients 
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Figure 2. Phylogram showing relationships between Hendra virus 
isolates, Australia, 2008, based on medium gene sequence. Scale 
bar indicates nucleotide substitutions per site.RESEARCH
received treatment with this drug. For these patients, the 
high-dose intravenous regimen was used, which was simi-
lar to that used for patients with Lassa fever (18). Although 
anemia developed in patient 1, the drug was well tolerated 
by patient 2. Furthermore, given a previously reported case 
of late-onset Hendra virus encephalitis (3), patient 2 was 
given prolonged oral therapy (to month 8), which was well 
tolerated. The in vivo efﬁ  cacy of ribavirin against Hendra 
virus remains unknown, although this drug delayed but 
did not prevent deaths caused by Nipah virus in a hamster 
model (19).
Although basal serum and CSF ribavirin concentrations 
>10 mg/L (during administration of ribavirin, 15 mg/kg 
every 6 h intravenously) and basal serum ribavirin concen-
trations of 6 mg/L (during administration of 8 mg/kg every 
8 h orally) were documented, these concentrations may be 
inadequate given the results of in vitro susceptibility test-
ing. The 90% inhibitory concentration of ribavirin against 
one of the human virus isolates was 64 mg/L, which was 
similar to that reported for an original human isolate from 
1994 (20).
Treatment with ribavirin was initiated early (before 
onset of encephalitis) for patient 2 but later (upon onset of 
encephalitis) in patient 1. However, the inﬂ  uence of this 
timing on outcome remains unclear, particularly given the 
uncertainty about activity of ribavirin against Hendra vi-
rus and other possible confounding factors. For example, 
patient 1 had different and possibly greater quantitative 
initial exposure to Hendra virus, earlier onset of encepha-
litis, and corticosteroid therapy that may have suppressed 
virus clearance. We also administered intravenous riba-
virin prophylactically for 5 days in another person after 
a percutaneous blood exposure to a horse documented as 
positive for Hendra virus by RT-PCR. This regimen was 
well tolerated, and follow-up assessments have not dem-
onstrated seroconversion.
We emphasize that the efﬁ  cacy of ribavirin as therapy 
or prophylaxis remains, at best, uncertain. However, given 
the absence of other available therapies, and the tolerabil-
ity of ribavirin, we advocate that it be given early in clini-
cal illness and be considered where high-risk exposure to 
Hendra virus has occurred. However, because only 6 cases 
have been recognized in humans, the criteria for high-risk 
exposure remain undeﬁ  ned.
This absence of established therapies underscores the 
need for early recognition of equine Hendra virus infec-
tion, implementation of infection control precautions, and 
prevention of horse-to-human transmission. Although the 
attack rate for humans exposed to infected horses in this 
outbreak (10%) was similar to that in the other document-
ed stable outbreak that caused human infection (at which 
time the causative pathogen had not been identiﬁ  ed) (2), 
upon recognition of the outbreak and implementation of 
protective measures, no further horse-to-human transmis-
sion occurred. 
Because this outbreak involved hitherto unrecognized 
equine manifestations with predominant neurologic disease 
in the relative absence of respiratory signs, equine case def-
initions have been revised to include either respiratory or 
neurologic manifestations or both (21). The degree of nu-
cleotide sequence variation observed between Hendra virus 
isolates from this and previous outbreaks suggests greater 
genomic variation than previously assumed. Whether the 
prominent encephalitic manifestations observed in this out-
break reﬂ  ect this genetic variability require further assess-
ment.
Detailed exposure histories from our 2 patients sug-
gest that the likely incubation period was 9–16 days, which 
was longer than previously estimated. Furthermore, both 
patients performed nasal cavity lavage of a horse during 
the 3 days before its onset of symptoms of infection with 
Hendra virus. This ﬁ  nding suggests that horses may be in-
fectious late in their incubation period, as observed with 
other Paramyxoviridae (e.g., measles).
The modes of horse-to-human transmission of Hen-
dra virus are not known completely, but likely result from 
direct contact with respiratory secretions and other equine 
tissue and ﬂ  uids or from droplet or aerosol exposure. Fur-
thermore, difﬁ  culties associated with clinical recognition of 
equine Hendra virus infection present challenging infection 
control implications for equine veterinary practice. There-
fore, routine adoption of infection control precautions en-
compassing hand washing, use of gloves and other forms 
of PPE, and a high index of clinical suspicion for equine 
Hendra virus infection are required. Although experience 
with human Hendra virus infection is relatively limited, no 
evidence exists of human-to-human transmission. How-
ever, persistence of Hendra virus RNA in NPA samples 
throughout the ﬁ  rst 2 weeks of illness indicates that health-
care workers potentially exposed to respiratory secretions 
should adopt PPE use to prevent exposure to droplets.
In conclusion, we describe severe Hendra virus infec-
tion in 2 veterinary workers, 1 who died, after exposure 
to infected horses. Given the absence of other established 
therapies, ribavirin was administered. However, further un-
derstanding of the pathogenesis of neurologic disease is re-
quired to guide potential therapies. These evolving equine 
clinical manifestations and the inevitable and increasing 
interactions between the natural host of the virus (fruit bat 
species) and horses will continue to challenge veterinary, 
public health, and medical communities.
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